France Commits €7 Billion to Health Innovation as Biotech Funding Slips 10%

France's government has committed US$7.8 billion (€7 billion) to health innovation under the France 2030 plan, even as the country's HealthTech companies raised 10% less in 2025 than the year before, taking in US$2.6 billion (€2.3 billion), of which US$1.2 billion came from venture capital.

The tension between state ambition and private-market contraction frames the current state of French biotechnology. According to the 2026 France HealthTech Panorama, the sector counts nearly 2,800 companies, yet around a third are less than five years old and more than half are very small entities with fewer than 10 employees. Only 10% of French biotechs have commercialized products; 27% remain at the research and proof-of-concept stage. In 2025, 20% of companies reported raising funds, down from 37% in 2024.

What does France 2030 actually promise?

The plan's targets are specific: make France Europe's leading country for clinical trials, develop at least five innovative biotherapies by 2030, double sector jobs, and produce one new unicorn and five new biotechs. It also establishes a Health Innovation Agency to manage health innovation strategically, funds preparedness for emerging infectious diseases and chemical, biological, radiological and nuclear threats, and aims to industrialize healthcare products domestically.

The commercial backdrop is substantial. France is the EU's second-largest pharmaceutical market at roughly US$72.7 billion (€65 billion) in 2025, and ranks fourth in Europe for industrial agreements, with 304 signed between 2021 and 2025, though only sixth by average value. It hosts Sanofi, Ipsen, Pierre Fabre and Servier, alongside research institutes Pasteur and Curie, diagnostics leader bioMérieux and the State University of New York at Buffalo spin-off Nanobiotix, listed on Euronext Paris since 2012 and later on Nasdaq.

Which deals defined the past year?

Strategic alliances have accelerated as funding tightened. Ipsen acquired US-based Kartos Therapeutics and Switzerland's Memo Therapeutics. Sanofi struck collaborations with EVOQ Therapeutics, Kali Therapeutics and Owkin, and invested in Sensorion. Servier partnered with start-up Kyron.bio. Osivax entered a long-term collaboration with South Korea's GC Biopharma on a next-generation seasonal influenza vaccine, and Transgene signed an immunotherapy deal with Japan's NEC.

The largest new arrangement: in October 2026, Enodia Therapeutics announced a research collaboration with Pfizer worth a potential US$500 million in upfront payments, milestones and tiered royalties to develop Sec61-targeting small molecules for targeted protein degradation. Enodia, built on Institut Pasteur research by Argobio Studio, had raised a US$25 million seed round in January 2026, co-led by Elaia, Pfizer Ventures and Bpifrance.

Who raised the biggest rounds?

• Abivax: US$920 million (€807 million) in an expanded public offering in July 2026, funding Phase 3 trials of obefazimod (miR-124) in ulcerative colitis. Phase 3 ABTECT data were presented in September; an NDA submission is planned by year-end 2026, with Phase 2b ENHANCE-CD topline results in Crohn's disease expected mid-2027.
• Nanobiotix: US$114.4 million (€98.6 million) public offering, plus a US$96.2 million follow-on in May 2026. Its J&J-partnered NBTXR3 (JNJ-1900) showed positive Part 1 data from the Phase 2 CONVERGE study at ESTRO 2026 in stage 3 inoperable NSCLC; the FDA accepted a protocol amendment to the pivotal NANORAY-312 head and neck study removing the interim analysis.
• Bionyra Pharma: US$165 million Series A, with Sanofi as investor. Founded in 2025 by Sofinnova Partners and former Sanofi R&D VP Frédéric Marrache, it licensed BYN-001 (anti-IL-25, IND-stage for atopic dermatitis) from NovaRock and two TL1A assets from TrueLab. BYN-002 reported positive interim Phase 1 results in October 2026; bispecific BYN-003 began Phase 1 in April 2026.
• Cyllene Therapeutics: US$38.3 million (€33 million) Series C in July 2026 for its HERMES non-replicating HSV-1 vector platform; lead candidate EG110A holds FDA RMAT designation and is in Phase 1/2 for neurogenic detrusor overactivity.
• Axoltis Pharma: US$20.9 million (€18 million) Series A in December 2025 for NX210c in ALS, following positive Phase 2 SEALS topline results in September 2026.
• Sensorion: €60 million financing in January 2026, including €20 million from Sanofi; a US IND filing for SENS-601 (GJB2-GT) gene therapy is planned by end-2026, with first patient dosing in the HearConnex trial by early 2027.
• Innate Pharma: US$75 million upfront from Sobi in August 2026 to license lacutamab in T-cell lymphoma, initiating the TELLOMAK-3 Phase 3 study expected in Q1 2027; monalizumab remains in the pivotal PACIFIC-9 Phase 3 with AstraZeneca, with readout updated to H1 2027.

What about AI and platform players?

Owkin, co-founded in 2016 by Thomas Clozel and Gilles Wainrib, became a unicorn in November 2021 after a US$180 million Sanofi investment and has since raised more than US$300 million from Google Ventures, Otium Capital and MACSF. In 2026 it signed three-year K Pro AI platform agreements with AstraZeneca (May), Sanofi (June), Boehringer Ingelheim (September) and Servier (September). Its sole disclosed clinical candidate, OKN4395, inhibits EP2, EP4 and DP1 prostanoid receptors in advanced solid tumors.

Kyron.bio, founded in 2022, raised a US$5.6 million seed in May 2025 for precision glycosylation control in antibodies, partnering with Servier.

Not every program advanced. In October 2026, Osivax reported that OVX836, its influenza nucleoprotein vaccine, failed as a standalone in a Phase 2b trial; the company, which has raised US$42.2 million, now pursues combination use only, through GC Biopharma and an undisclosed global pharmaceutical company.

The France 2030 plan recognizes that the country's strengths in biology, immunology and genomics remain under-commercialized. With targeted capital, clinical-trial infrastructure and manufacturing investment, France could become Europe's leading biopharmaceutical innovation hub rather than a research nation whose discoveries are commercialized elsewhere.